Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients

Diabetes Research and Clinical Practice

Volumn 36, Issue 1, 1997, Pages 11-18

  Hirano, Tsutomu ^a   Kashiwazaki, Kouichi ^a   Moritomo, Yasunori ^a   Nagano, Seishi ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetic nephropathy; Factor VII; Fibrinogen; Insulin resistance; PAI 1

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRINOGEN; GLUCOSE; INSULIN; OCTREOTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; TRIACYLGLYCEROL BLOOD LEVEL;

ALBUMINURIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FACTOR VII; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIGLYCERIDES;

EID: 0031128130     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(97)01384-3     Document Type: Article

References (32)

1. [1] Borch-Johnsen, K., Andersen, P.K. and Deckert, T. (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus, Diabetologia 28, 590-596.
2. [2] Jensen, T., Borch-Johnsen, K., Kofoed-Enevoldosen, A. and Deckert, T. (1987) Coronary disease in young Type 1 (insulin-dependent) patients with and without diabetic nephropathy-Incidence and risk factors. Diabetologia 30, 144-145.
3. [3] Mattock, M., Morrish, N., Viberti, G.C., Keen, H., Fitzgerald, A. and Jackson, G. (1992) Prospective study of microalbuminuia as predictor of mortality in NIDDM. Diabetes 41, 736-741.
4. [4] Pinkney, J.H., Foyle, W-J., Denver, A.E., Mohamed-Ali, V., McKinlay, S. and Yudkin, J.S. (1995) The relationship of urinary albumin excretion rate to ambulatory blood pressure and erythrocyte sodium-lithium counter-transport in NIDDM. Diabetologia 38, 356-362.
5. [5] Jensen, T., Stender, S. and Deckert, T. (1988) Abnormalities in plasmas concentrations of lipoproteins and fibrinogen in Type 1(insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 31, 142-145.
6. [6] Deckert, T., Kofoed-Enevordsen, A., Norgaard, K., Borch-Johnsen, K., Feldt-Rasmussen, B. and Jensen, T. (1992) Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care 15, 1181-1191.
7. [7] Kruithof, E.K.O. (1988) Plasminigen activator inhibitors-a review. Enzyme 40, 113-121.
8. [8] Rapaport, S.I. and Rao, L.V.M. (1992) Initiation and regulation of tissue factor-dependent blood coagulation. Artherioscler. Thromb. 12, 1111-1121.
9. [9] Smith, E.B. (1986) Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin. Haematol. 15, 355-370.
10. [10] Hamsten, A. (1993) The hemostatic system and coronary heart disease. Thromb. Res. 70, 1-38.
11. [11] Ernst, E. and Resch, K.L. (1993) Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann. Intern. Med. 118, 956-963.
12. [12] Hamsten, A., Wiman, B., Defaire, U., Blomback, M. (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313, 1557-1563.
13. [13] Meade, T.W., Mellows, S., Brozovic, M. et al. (1986) Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet ii. 533-537.
14. [14] Meade, T.W., Ruddock, V., Stirling, Y., Chakrabarti, R. and Miller G.J. (1993) Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342, 1076-1079.
15. [15] Negri, M., Pasquale Arigliano, L., Talamini, G., Carlini, S., Manzato, K. and Bonadonna, G. (1993) Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels. Atherosclerosis 99, 55-61.
16. [16] Asplund-Carlson, A., Hamsten, A., Wiman, B. and Carlson, L.A. (1993) Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity:studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 36, 817-825.
17. [17] Juhan-Vague, I., Alessi, M.C. and Vague, P. (1991) Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34, 457-462.
18. [18] Potter van Loon, B.J., Kluft, C., Radder, J.K., Blankenstein, M.A. and Meinders. A E. (1993) The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42, 945-999.
19. [19] Juhan-Vague, I., Thompson, S.G. and Jespersen, J. (1993) On Behalf of the ECAT Angina Pectoris Study Group: Involvement of the hemostatic system in the insulin resistance syndrome. Arterioscler Thromb. 13, 1865-1873
20. [20] Attman, P-O., Nyberg, G., William-Olsson, T., Knight-Gibson, C. and Alaupovic, P. (1992) Dyslipoproteinemia in diabetic renal failure. Kidney Int. 42, 1381-1389.
21. [21] Hirano, T., Naito, H., Kurokawa, M., Ebara, T., Nagano, S., Adachi, M. and Yoshino G (1996) High prevalence of small LDL particles in non-insulin dependent diabetic patients with nephropathy. Atherosclerosis 123, 57-72
22. [22] Groop, L., Ekstrand, A., Forsblom, C., Widen, E., Groop, P.H., Teppo, A.M. and Eriksson, J. (1993) Insulin resistance, hypertension and microalbuminuria in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36, 642-647.
23. [23] Declerck, P.J., Alessi, M.C., Verstreken, M., Kruithof, B.K.O. and Juhan-Vague, I. (1988) Collen Desire: Measurement of plasminogen activator inhibitor I in biologic fluids with a murine monoclonal antibody-Based enzyme-linked immunosorbent assay. Blood 71, 220-225.
24. [24] Dati, F., Barthels, M., Conard, J. et al. (1987) Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time. Thromb. Haemostas. 58, 856-865.
25. [25] Clauss, Von A. (1957) Gerinnungsphysiologische Schnell-methode zur Bestimmung des Fibrinogens. Acta Haemat. 17, 297-246.
26. [26] Gruden, G., Cavallo-Perin, P. Bazzan, M., Stefania, S. and Vuolo A. (1994) PAI-I and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 43, 426-429.
27. [27] Kario, K., Matsuo, T., Kobayashi, H., Matsuo, M., Sakata, K. and Miyata, T. (1995) Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependeni diabetic patients with microalbuminuria. Artherioscler. Thromb. Vasc. Biol. 15, 1114-1120.
28. [28] Panahloo, A., Mohamed-Ali, V., Lane, A., Green, F., Humphries, S.E. and Yudkin, J.S. (1995) Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 44, 37-42.
29. [29] Reaven, G. (1988) Role of insulin resistance in human disease. Diabetes 37, 1595-160.
30. [30] DeFronzo, R.A. and Ferranini, E. (1991) Insulin resistance: A multifaceted syndrome responsible for NIDDM. obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, 173-94.
31. [31] Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T. and Kofoed-Enevoldsen, A. (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32, 219-226.
32. [32] Marsh, J.B. and Drabkin, D.K. (1960) Experimental reconstruction of metabolic patterns of lipid nephrosis. Key role of hepatic protein synthesis in hyperlipidemia. Metabolism 9, 946-955.